Nanobiotix S.A (NANO) - Total Assets
Based on the latest financial reports, Nanobiotix S.A (NANO) holds total assets worth €45.17 Million EUR (≈ $52.81 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Nanobiotix S.A - Total Assets Trend (2011–2024)
This chart illustrates how Nanobiotix S.A's total assets have evolved over time, based on quarterly financial data. Also see NANO stock market capitalisation for the company's overall valuation and market capitalisation.
Nanobiotix S.A - Asset Composition Analysis
Current Asset Composition (December 2024)
Nanobiotix S.A's total assets of €45.17 Million consist of 91.2% current assets and 8.8% non-current assets. Review debt load of Nanobiotix S.A to assess the company's total debt and financial obligations.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €44.43 Million | 73.8% |
| Accounts Receivable | €8.54 Million | 12.7% |
| Inventory | €0.00 | 0.0% |
| Property, Plant & Equipment | €5.54 Million | 8.2% |
| Intangible Assets | €7.00K | 0.0% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2011–2024)
This chart illustrates how Nanobiotix S.A's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See NANO stock price and chart for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Nanobiotix S.A's current assets represent 91.2% of total assets in 2024, an increase from 80.1% in 2011.
- Cash Position: Cash and equivalents constituted 73.8% of total assets in 2024, up from 30.8% in 2011.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2011.
- Asset Diversification: The largest asset category is cash and equivalents at 73.8% of total assets.
Nanobiotix S.A Competitors by Total Assets
Key competitors of Nanobiotix S.A based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $10.03 Billion |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.98 Billion |
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
|
USA | $792.26 Million |
|
Nanobiotix
NASDAQ:NBTX
|
USA | $67.76 Million |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253
|
China | CN¥2.23 Billion |
Nanobiotix S.A - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.63 | 1.42 | 2.06 |
| Quick Ratio | 0.63 | 1.38 | 2.06 |
| Cash Ratio | 0.38 | 1.17 | 0.00 |
| Working Capital | €-23.15 Million | €23.94 Million | €18.13 Million |
Nanobiotix S.A - Advanced Valuation Insights
This section examines the relationship between Nanobiotix S.A's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 61.99 |
| Latest Market Cap to Assets Ratio | 20.56 |
| Asset Growth Rate (YoY) | -28.2% |
| Total Assets | €67.42 Million |
| Market Capitalization | $1.39 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Nanobiotix S.A's assets at a significant premium (20.56x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Nanobiotix S.A's assets decreased by 28.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Nanobiotix S.A (2011–2024)
The table below shows the annual total assets of Nanobiotix S.A from 2011 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | €67.42 Million ≈ $78.82 Million |
-28.20% |
| 2023-12-31 | €93.90 Million ≈ $109.78 Million |
+57.10% |
| 2022-12-31 | €59.77 Million ≈ $69.88 Million |
-41.21% |
| 2021-12-31 | €101.67 Million ≈ $118.86 Million |
-24.08% |
| 2020-12-31 | €133.93 Million ≈ $156.57 Million |
+138.84% |
| 2019-12-31 | €56.07 Million ≈ $65.56 Million |
+21.39% |
| 2018-12-31 | €46.20 Million ≈ $54.01 Million |
-19.61% |
| 2017-12-31 | €57.47 Million ≈ $67.18 Million |
+89.02% |
| 2016-12-31 | €30.40 Million ≈ $35.54 Million |
+15.08% |
| 2015-12-31 | €26.42 Million ≈ $30.89 Million |
-28.70% |
| 2014-12-31 | €37.05 Million ≈ $43.32 Million |
+398.12% |
| 2013-12-31 | €7.44 Million ≈ $8.70 Million |
-46.96% |
| 2012-12-31 | €14.02 Million ≈ $16.40 Million |
+381.38% |
| 2011-12-31 | €2.91 Million ≈ $3.41 Million |
-- |
About Nanobiotix S.A
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esop… Read more